Longer-term follow-up presented at the 2025 ASH Annual Meeting indicates that a gilteritinib triplet—gilteritinib plus venetoclax and azacitidine—achieved a 29.7-month median overall survival in newly diagnosed FLT3-mutated acute myeloid leukemia. The update centers on durability of benefit rather than early response metrics. The data position the regimen as a high-interest option in a disease space where durable control remains the key differentiator among targeted combinations. For clinicians and researchers, it also sets expectations for what trial endpoints may look like as frontline AML studies increasingly report extended follow-up. Biotech stakeholders will likely focus next on how patient subgroups responded, whether survival benefits translate into progression-free outcomes, and how evolving standard-of-care comparisons shape future trial design.